(Q45839222)

16 December 2017

title

Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity (English)

1 reference

16 December 2017

1 reference

vaccinia virus

1 reference

Shimizu Y

1

1 reference

16 December 2017

Hasumi K

series ordinal

2

1 reference

16 December 2017

Masubuchi K

series ordinal

3

1 reference

16 December 2017

Okudaira Y

series ordinal

4

1 reference

16 December 2017

language of work or name

English

0 references

publication date

1 November 1988

1 reference

16 December 2017

European Journal of Immunology

published in

1 reference

16 December 2017

volume

18

1 reference

16 December 2017

issue

11

1 reference

16 December 2017

page(s)

1773-1778

1 reference

16 December 2017

Induction of immune responsiveness in a genetically low-responsive tumor-host combination by chemical modification of the immunogen

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

Enhanced immunogenicity of chemically-coated syngeneic tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

The augmentation of tumor-specific immunity by virus help. I. Demonstration of vaccinia virus-reactive helper T cell activity involved in enhanced induction of cytotoxic T lymphocyte and antibody responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

The augmentation of tumor-specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus-reactive helper T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

Further investigations on the mode of entry of vaccinia virus into cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830181118

7 January 2021

Identifiers

DOI

10.1002/EJI.1830181118

1 reference

16 December 2017

1 reference

16 December 2017